Capital Investment Advisors 13F: Cuts JNJ Stake by $4.2M
Key Points
- Capital Investment Advisors trimmed its Johnson & Johnson stake by 3.8% during the quarter, bringing its holding down to 398,735 shares valued at about $105.6 million.
- Johnson & Johnson shares recently traded around $263.85, sitting about 6.1% below their 52-week high of $281.07.
- Wall Street analysts hold a consensus buy rating on the healthcare giant with a mean price target of $279.41 ahead of its next earnings report.
Since the filing, $JNJ is down 1.4% to date (from the $267.61 close on Oct 22, 2026).
Get Johnson & Johnson text alerts
We text you when insiders, Congress, analysts or big funds move on $JNJ.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Johnson & Johnson alert may contain errors. Disclosures
Capital Investment Advisors trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 15,883 shares during the quarter, according to a Form 13F filing with the SEC on October 22, 2026. The firm owned 398,735 shares of the healthcare giant at the end of the period, down from 414,618 shares previously. The remaining position carried a reported value of $105,561,063.00.
JNJ
Johnson & Johnson
Capital Investment Advisors vs. the S&P 500
Hypothetical returns from Capital Investment Advisors's disclosed trades, not real profit or advice. How we model this.
What Changed in Capital Investment Advisors's Johnson & Johnson Position
The reduction marked a 3.8% cut to the firm's holdings in Johnson & Johnson during the reported quarter. Capital Investment Advisors held 414,618 shares prior to the adjustment. Even after the sale, the firm maintains a notable investment in the drug manufacturer valued in the nine-figure range.
Other Institutional Activity in Johnson & Johnson
Other major investors also adjusted their positions in Johnson & Johnson around the same period. Fort Washington Investment Advisors grew its holdings by 539,918 shares, ending with 404,591 shares worth about $107,111,429.00. Fjarde Ap-Fonden /Fourth Swedish National Pension Fund reduced its stake by 151,529 shares to hold 1,105,140 shares valued at approximately $292,574,764.00. Assenagon Asset Management S.A. grew its holdings by 1,051,362 shares, ending with 2,990,726 shares worth about $791,764,801.00. Smith Chas P & Associates Pa Cpas grew its holdings by 7,129 shares, ending with 238,267 shares worth about $60,891,434.00. SBI Securities grew its holdings by 10,021 shares, ending with 122,412 shares worth about $32,407,353.00.
Johnson & Johnson Stock Up 2.4%
Johnson & Johnson shares recently traded around $263.85 as of October 24, 2026. The stock closed at $267.61 on the October 22 filing date. The recent price sits about 1.4% below that filing-day close and 6.1% below its 52-week high of $281.07. At the same time, the shares trade above their 52-week low of $184.66 and hold above their 200-day moving average of $245.19.
Recent Earnings
Johnson & Johnson generated trailing-twelve-month revenue of $99.3 billion alongside earnings of $6.59 per share. The company posted a net profit margin of 16.2% and a return on equity of 57.7%. The next quarterly earnings report is scheduled for January 26, 2027.
Dividend
Johnson & Johnson pays an annual dividend rate of $5.36 per share, translating to a dividend yield of 2.0%. The company's payout ratio stands at 80.1% of earnings.
Insider Buying and Selling at Johnson & Johnson
Company insiders executed several transactions prior to the filing date. Officer Elizabeth Forminard sold 15,918 shares on August 6, 2026, for a total of $4,090,960.00. Chief Executive Officer Joaquin Boix Duato disposed of 123,291 shares on August 13, 2026, totaling $32,199,927.00. Officer Jennifer L. Taubert sold 15,000 shares at an average price of $263.36 on August 17, 2026, worth $3,950,400.00. Officer Timothy Schmid parted with 33,597 shares at $274.74 each on September 2, 2026, for a total value of $9,230,440.00.
Analysts Set New Price Targets
Wall Street firms updated their views ahead of the filing period. On October 14, 2026, Leerink Partners maintained an outperform rating while lowering its price target from $276.00 to $272.00. Wells Fargo maintained an overweight rating on October 14, 2026, trimming its target from $282.00 to $275.00. RBC Capital kept an outperform rating on October 14, 2026, lowering its target from $290.00 to $280.00. Morgan Stanley maintained an overweight rating on October 15, 2026, adjusting its target from $294.00 to $292.00. Wells Fargo later updated its stance on October 16, 2026, raising its overweight target from $275.00 to $287.00. Overall, the stock carries a consensus buy rating and a mean price target of $279.41 across 22 analyst opinions.
About Johnson & Johnson
Johnson & Johnson is a healthcare company based in New Brunswick, New Jersey. The company researches, develops, manufactures, and sells a wide range of medical products and pharmaceuticals worldwide. Its operations are divided into two main segments: Innovative Medicine and MedTech. Institutional portfolio moves like this one reflect ongoing rebalancing by professional managers across large healthcare holdings.
Bottom Line
Investors will look toward the company's next earnings report on January 26, 2027, for further updates on revenue and margins. Tracking future SEC filings will show whether institutional sentiment toward the drug manufacturer shifts further in the coming quarters.
Related Filing Alerts
Source: Capital Investment Advisors's 13F filing on $JNJ (Oct 22, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts